Abstract
Background A signal of myocarditis and pericarditis following mRNA COVID-19 vaccines first emerged in Israel in May 2021. Further cases have since been reported in multiple countries. The reporting rates of these events indicate that they are very rare given the high numbers of vaccinated persons. Males and younger vaccinees appear more frequently affected, more often following the second vaccine dose. As vaccine programmes progress with the focus shifting to younger people, it is possible that more cases of myocarditis and pericarditis will be reported.
Objectives To bring together spontaneously reported data from around the world to estimate the reporting rate in different countries and better understand the risk factors for myocarditis and pericarditis following exposure to COVID-19 mRNA vaccines.
Methods Spontaneous reports from the United Kingdom, United States, and European Economic Area were used to estimate the frequency of myocarditis and pericarditis reported following COVID-19 Vaccine Pfizer/BioNTech and COVID-19 Vaccine Moderna. Cases were stratified by age, sex, and vaccine dose where data were available. Reporting rates amongst vaccinees receiving mRNA vaccines in each region were estimated.
Results A small number of reports of myocarditis and pericarditis had been submitted to each database examined. These events are very rare according to reporting rates of spontaneous adverse reactions. The events were more frequently reported amongst males, and most reports came from vaccinees aged under 30 years. The typical clinical course of these events is mild, with full recovery in most cases.
Conclusions This study provides evidence that younger vaccinees more frequently report myocarditis and pericarditis following mRNA COVID-19 vaccines compared with older vaccinees. These very rare events with mild clinical course followed by full recovery in most cases were more frequent following the second dose. Reporting rates of myocarditis and pericarditis were consistent between the data sources.
What is already known on this topic?
What is already known on this topic?
A signal of myocarditis and pericarditis following mRNA COVID-19 vaccines first emerged in May 2021.
A small number of myocarditis and pericarditis events have been reported to spontaneous reporting systems of the United Kingdom, United States, and European Union/European Economic Area.
Males and younger vaccinees appear more frequently affected, more often following the second vaccine dose.
These events are typically mild, with full recovery in most cases.
What this study adds
What this study adds
This study brings together spontaneously reported data from multiple regions to provide evidence that younger vaccinees more frequently report myocarditis and pericarditis following mRNA COVID-19 vaccines compared with older vaccinees.
Reporting rates of myocarditis and pericarditis suggest the events are very rare.
Competing Interest Statement
All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: The Drug Safety Research Unit (DSRU) is a registered independent charity (No. 327206) associated with the University of Portsmouth. The DSRU receives donations and grants from pharmaceutical companies; however, the companies have no control over the conduct or publication of its studies. The DSRU has received grants to conduct unconditional studies on the Oxford/AstraZeneca COVID-19 vaccine and is in negotiations to receiving grants for conducting CPRD studies for Pfizer, Moderna, and Janssen COVID-19 vaccines. The DSRU has conducted benefit-risk studies on products for COVID-19, including remdesivir, lopinavir/ritonavir, chloroquine and hydroxychloroquine, and convalescent plasma. Professor Shakir is the principal investigator for an active surveillance study for the Oxford/AstraZeneca vaccine, but this assessment is unrelated to this study. Professor Shakir has been a member of Data Safety Monitoring Boards for Ipsen, Biogen, and Diurnal. None of these companies have any involvement with COVID-19 vaccines. Professor Shakir was invited by AstraZeneca to advise on the events of thrombosis with thrombocytopenia with the COVID-19 vaccine and to be a member of an advisory committee on a safety study of the Oxford/AstraZeneca vaccine in Europe. Samantha Lane has no conflicts of interest with regard to this study.
Funding Statement
No external funding was received for the preparation of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was not required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No further data are available.
